EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

EU regulators have issued a positive opinion for the extension of the market authorization for subcutaneous formulation of ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...

substitution mutations. 3 Following a three-year period within the Cancer Drugs Fund (CDF), this recommendation means that osimertinib has successfully exited the CDF, enabling full baseline ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...

exon 19 deletions or exon 21 substitution mutations. The NICE decision was supported by data from the Phase III ADAURA trial (NCT05120349), which demonstrated that post-surgical treatment with ...

We have discovered two types of 5′ intronic gene mutation that impair androgen receptor (AR) mRNA expression severely, and cause complete androgen insensitivity. Labium majus skin fibroblasts ...

A screen of a comprehensive library of rubisco variants (each with a different single-amino-acid mutation), expressed ... a single amino-acid substitution can thus have consequences on an ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

The indication applies to advanced or metastatic cases involving epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R (L858R) substitution mutations. The approval is ...